key: cord-0258588-9wnpn9xa
authors: Renz, B. W.; Adrion, C.; Klinger, C.; Ilmer, M.; D'Haese, J.; Buhr, H.-J.; Mansmann, U.; Werner, J.; group, PyloResPres study
title: Pylorus resection versus pylorus preservation in pancreatoduodenectomy (PyloResPes): study protocol and statistical analysis plan for a German multicentre, single-blind, surgical, registry-based randomised controlled trial
date: 2021-08-07
journal: nan
DOI: 10.1101/2021.08.05.21260575
sha: 310e671279a776e349f881ea5631d6df0f6de0fd
doc_id: 258588
cord_uid: 9wnpn9xa

Introduction Partial pancreatoduodenectomy (PD) is the treatment of choice for various benign and malignant tumours of the pancreatic head or the periampullary region. For reconstruction of the gastrointestinal passage, two stomach preserving PD variants exist: pylorus preservation (ppPD), or pylorus resection (prPD) with preservation of the stomach. In pancreatic surgery, delayed gastric emptying (DGE) remains a serious complication after PD with an incidence varying between 4.5% and 45%, potentially delaying hospital discharge or further treatment, e.g. adjuvant chemotherapy. Evidence is lacking to assess which variant of PD entails fewer postoperative DGE. Methods and analysis The protocol of a large-scale, multicentre, pragmatic, two-arm parallel-group, registry-based randomised controlled trial (rRCT) using a two-stage group-sequential design is presented. This patient-blind rRCT aims to demonstrate the superiority of prPD over ppPD with respect to the overall incidence of DGE within 30 days after index surgery in a German real-world setting. A total of 984 adults undergoing elective PD for any indication will be randomised in a 1:1 ratio. Patients will be recruited at about 30 hospitals being members of the StuDoQ|Pancreas registry established by the German Society of General and Visceral Surgery (DGAV). The postoperative follow-up for each patient will be 30 days. The primary analysis will follow an intention-to-treat approach and applies a binary logistic random intercepts model. Secondary perioperative outcomes include overall severe morbidity (Clavien-Dindo classification), blood loss, 30-day all-cause mortality, postoperative hospital stay, and operation time. Complication rates and adverse events will be closely monitored. Ethics and dissemination This protocol was approved by the leading ethics committee of the Medical Faculty of the Ludwig-Maximilians-University, Munich (reference no. 19-221). The results will be published in a peer-reviewed journal and presented at international conferences. Study findings will also be disseminated via the website (http://www.dgav.de/studoq/pylorespres/). Trial registration number DRKS-ID: DRKS00018842 (https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00018842, prospectively registered on 24-Oct-2019)

1 For resection of malignant or benign lesions of the pancreatic head and the periampullary region, partial 2 pancreatoduodenectomy (PD) is commonly performed. 1,2 Due to the functional impairment of the 3 physiological propulsive action of the stomach and especially the pylorus, delayed gastric emptying 4 (DGE), 3,4 with an incidence varying from 4.5% to 45%, 5 remains a common serious complication after 5 PD. The mechanisms of DGE after PD are multifactorial and still remain unsolved. The left pylorus with 6 its physiological closing function could be a cause. Although not being life-threatening, DGE causes 7 impairment of oral intake often resulting in nausea and vomiting, and is therefore associated with an 8 extended hospital length of stay (LOS), higher healthcare costs and a delay of a potential postoperative 9 adjuvant therapy for tumour patients which may have a negative impact on survival. 6 10 There are two gastric resection strategies to perform PD: resection (prPD) or preservation of the pylorus 11 (ppPD). Intriguingly, the benefit of pylorus preservation or pylorus resection in PD with regard to the 12 risk of DGE is still controversially discussed. 5,7,8 A recent meta-analysis of eight non-randomised studies 13 revealed superiority for prPD compared to ppPD. 5 However, the subgroup of only three RCTs showed 14 no difference between both procedures regarding DGE. Particularly in the German prospective single-15 centre PROPP trial, prPD did not reduce the incidence or severity of DGE, but rather tended to have a 16 higher DGE rate. 8 On the other hand, according to a recent network meta-analysis of randomised trials, 17 prPD seems to be associated with lower rates of DGE. 9 In line with these inconclusive results, the 18 identified RCTs comparing ppPD and prPD have several limitations arising from clinical and 19 methodological heterogeneity. So far, no high-quality multicentre patient-blinded RCTs exist aiming to 20 prove or disprove the superiority of prPD compared to ppPD for reducing DGE or other major patient-21 relevant complications. 22

To fill this evidence gap and to generate clinical knowledge on the safety aspects and performance of 23 different reconstruction techniques in PD from a large-scale multicentre RCT, the registry-based 24

PyloResPres trial was initiated. This project is funded by the German Research Foundation (DFG grant 25 number WE 2008/9-0). The German Society for General and Visceral Surgery (DGAV) founded the 26 national pancreatic surgery registry StuDoQ|Pancreas as a valid platform for risk-adjusted quality 27 assessment, collaborative quality improvement, and outcomes research in pancreatic surgery. [10] [11] [12] [13] This 28 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 7, 2021. ; https://doi.org/10.1101/2021.08.05.21260575 doi: medRxiv preprint multicentre registry represents a major proportion of the PD patients in Germany at medium-and high-1 volume centres. Embedding the PyloResPres trial in this national registry cohort and employing the 2 already established und implemented electronic case report form (eCRF) is highly efficient and cost-3 effective in contrast to a conventional RCT. 14 We present the rationale and design of the PyloResPres 4 trial to investigate whether pylorus resection is advantageous over pylorus preservation in reducing the 5 DGE risk and regarding further postoperative patient-relevant outcomes after PD. 6 7 8

This protocol is presented in accordance with the SPIRIT Statement 15 and also considers the protocol-10 related aspects of the CONSORT extension for routinely collected data, adaptive designs, and non-11 pharmacological treatment interventions. [16] [17] [18] The trial will be carried out in accordance with Good 12

Clinical Practice and applicable German legislation. 13 14

The primary objective of the trial is to determine whether the incidence of DGE within 30 days after 16 index surgery in patients undergoing elective PD is lower with resection of the pylorus (pr) compared to 17 its preservation (pp). 18

19

PyloResPres is an investigator-initiated, large-scale, multicentre, 2-arm parallel-group, patient-blind, 21 adaptive (two-stage group-sequential), randomised controlled trial conducted in hospitals throughout 22

Germany. This surgical trial is designed as a registry-based RCT (rRCT) to imbed the study population 23

in the spectrum of a real-world PD registry cohort. Its design is also highly pragmatic in the sense of not 24 giving technical instructions on how the pancreatic head resection or the reconstruction should be 25 performed, i.e. limiting deviations from standard of care. 26 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 7, 2021. ; https://doi.org/10.1101/2021.08.05.21260575 doi: medRxiv preprint 1

This registry-based RCT allows recruiting patients from an unselected target population treated in 3 hospitals of all care levels (basic, regular, and maximum) including specialized high-volume centres. All 4 patients scheduled for an elective PD who are eligible and consented for being registered in 5

StuDoQ|Pancreas will be consecutively assessed for eligibility and informed about the trial details 6 during a pre-treatment visit or on the day of admission to the hospital's surgical department. The 7

following eligibility criteria were defined for the trial: 8

Age ≥18 years; 10 planned partial pancreatoduodenectomy for any indication (e.g. resectable benign or malign 11 tumour of the pancreatic head or the periampullary region); 12

Written informed consent of the patient or legal representative. 13

Age <18 years; 15

Patients participating in another interventional trial interfering with the surgical intervention or 16 the outcomes of this trial; 17

Patients with expected lack of compliance and/or irreconcilable language barriers. 18

By defining less stringent inclusion criteria, almost the whole spectrum of diseases in the pancreatic 19 head region is of interest. The trial population is covered by the multicentre DGAV StuDoQ|Pancreas 20 registry which provides representative data on pancreatic surgery in academic and non-academic 21 hospitals with a medium to high institutional and surgeon caseload, while capturing about 20% of all 22 pancreatic resections performed annually in Germany. 10 The registry is recognized by surgeons as a 23 valuable tool to assess institutional quality and effectiveness of pancreatic surgery and surgical 24 interventions and has received significant acceptance. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 7, 2021. ; https://doi.org/10.1101/2021.08.05.21260575 doi: medRxiv preprint

All institutions participating in the StuDoQ|Pancreas registry (currently, about 70 pancreatic surgery 2 centres) are required to meet certain quality standards and are basically deemed eligible. 10,11 These sites 3 are centres for pancreatic surgery at academic and non-academic community hospitals with a medium to 4 high caseload, at least fulfilling the criteria to participate in the StuDoQ|Pancreas registry. 19 Ultimately, 5 about 30 registry sites with an annual caseload of about 900 PDs were recruited from the set of eligible 6 hospitals according to their letter-of-intent written during the project application, and further expansion 7 is to be expected if necessary (Supplemental File 1). 8 9

Patients fulfilling the eligibility criteria will be randomly assigned in a ratio of 1:1 to receive one of the 11 two intestinal reconstruction techniques after PD. The randomisation technique is based on permuted 12 balanced blocks and considers stratification by study site. The randomisation list was created by an 13 independent person at the IBE who is not involved into the trial and is concealed from study 14 investigators, other study personnel (e.g. study nurses), data managers and the responsible trial 15 statistician. Neither the investigators nor other trial staffs have access to the randomisation list. 16

Randomisation will be undertaken via the secure, web-based eCRF system REDCap® (Research 17 Electronic Data Capture; Version 9.5.4, Vanderbilt University, Nashville, Tenn.) hosted at the IBE of 18 the LMU Munich (https://random.ibe.med.uni-muenchen.de/redcap/). Depending on local organisational 19 circumstances, randomisation takes place up to one day before the index surgery, or intraoperatively 20 (prior to the step under investigation, i.e. after exploration and mobilisation of the duodenum and the 21 pancreatic head when preservation of the pylorus seems technically and oncologically feasible), after 22 assessing a patient for eligibility and after entering his/her screening data into the official 23

StuDoQ|Pancreas eCRF (i.e., creating a new patient identifier). The randomising clinician or study nurse 24 at the study site will log into the REDCap system that will randomise an eligible patient to the ppPD or 25 prPD group, and will notify the operating surgeon about the intervention allocation for the patient. To 26 verify the actually performed surgical procedure compared to the allocated intended one, the correct 27 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 7, 2021. ; https://doi.org/10.1101/2021.08.05.21260575 doi: medRxiv preprint randomisation (intended and actual allocation) will be assessed by the histopathological report written 1 by an independent pathologist unaware of the allocated intervention. This report will be reviewed by the 2 monitor for quality control. 3 4 By nature of the trial design and the surgical intervention, it is not possible to blind the investigators and 5 study personnel at the hospital. Patients will be blinded to the intervention until discharge and 6 assessment of the primary and secondary endpoints. No attempts will be made to blind the trial 7 statisticians. However, they will not have access to the unblinded eCRF and database during the study 8 and will perform analyses according to a predefined statistical analysis plan (SAP) which will be 9 finalised prior to database closure at latest. Although investigators/healthcare providers, outcome 10 assessors, data managers and data analysts (affiliated to the DGAV and IBE, respectively) will not be 11 blinded, we do not expect a high risk of ascertainment bias to influence the treatment effect for objective 12 outcomes including the primary outcome. 20 13 14

This trial compares two established and routinely performed surgical approaches, with prPD being the 16 experimental procedure and ppPD the control procedure. The board certified surgeon participating in the 17 trial must have the same level of expertise in both techniques to avoid a significant bias due to learning 18

In both treatment groups, the resection of the duodenum with the head of the pancreas, the first 20 15−30cm of the jejunum, the common bile duct, the gallbladder, and in oncological cases the 21 locoregional and central lymph node dissection, will be performed according to the local standards. In 22 contrast, the transection of the proximal end of the gastrointestinal tract has to be performed according 23

to the allocated treatment. Furthermore, a pancreatojejunostomy or pancreatogastrostomy and a 24 hepaticojejunostomy will be carried out to connect the pancreas and the bile duct with the intestinal tract 25 in accordance to the standardized approach at the respective study site. 26 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 7, 2021. ;

The duodenum will be divided (e.g. with a linear stapling device) at least 1cm distal to the pylorus, 3

preserving the gastric vessels along the lesser and the greater curvature. After performing the pancreatic 4 anastomosis (pancreatojejunostomy or pancreatogastrostomy) and the hepaticojejunostomy, the 5 gastrointestinal passage can be reconstructed through a standard Roux-en-Y reconstruction or as a 6 single-loop omega-shaped reconstruction with or without an additional side-to-side jejunojejunal 7 anastomosis (Figure 1a-c) . Regarding the duodenojejunostomy, it is left up to the standard at the 8 respective surgical department whether continuous or interrupted sutures in a single layer or two layer 9 technique are employed, or whether the duodenal staple line is included or excluded from the 10 anastomosis. The route of reconstruction must be documented in the StuDoQ|Pancreas registry eCRF. 11

The ppPD is well-chosen as the reference treatment as it is regarded as the standard treatment for 12 resectable tumours of the pancreatic head and the periampullary region. 22 13 14

In the prPD group, the stomach will be divided within 5cm proximal to the pyloric ring (e.g. with a 16 linear stapling device) with complete preservation of the gastric vessels along both curvatures to 17 maintain perfusion of the distal stomach via the gastroepiploic vessels and the left gastric artery, 18 respectively. As in the ppPD group, the pancreatic and bile duct anastomosis will be performed. Similar 19 to the control group, reconstruction can be established through a standard Roux-en-Y reconstruction or 20 as a single-loop omega-shaped reconstruction, but in contrast to the ppPD group, an additional side-to-21 side jejunojejunal anastomosis has to be performed (Figure 1d and e) . Similar to the ppD group, the 22 technique of the duodenojejunostomy will be left up to the preferences of the participating surgery 23 department. The route of reconstruction must also be documented in the eCRF. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 7, 2021. ;

Due to intraoperative circumstances and disease severity, not all patients randomised will receive the 3 assigned intervention reflecting clinical reality. This is particularly true in the case of pre-operative 4 randomisation. If a patient is randomised on the day before surgery to receive ppPD, the surgeon will 5 have to confirm that PD is feasible, and preservation of the pylorus is technically possible and 6 oncologically justified. Otherwise, the surgeon will have to convert from ppPD to prPD. Reasons for 7 conversion can arise intraoperatively, e.g., for technical infeasibility or significant bleeding. Affected 8 trial participants will be denoted as 'crossover patients'. In the case of a pre-operative randomisation, a 9 patient can also turn out to be non-resectable or having a previously unknown metastatic disease, and 10 neither of the two surgical procedures investigated can be undertaken. The reason for all deviations 11 between the intended and actual allocation will be documented in the eCRF. If a pre-operatively 12 randomised patient does not receive the intended treatment or even neither of the treatments, he or she 13 remains in the trial until the end of the follow-up period. 21 14 15

Due to the pragmatic attitude of this rRCT, no instructions or recommendations on the perioperative 17 management of the patients will be given. Hence, no permitted or prohibited procedures exist. Peri-and 18 postoperative medical treatment including antibiotic medication, prokinetic drugs and somatostatin 19 analogues should be administered according to the respective institutional standards, but must be 20 documented in the registry. Furthermore, endoscopic examination of the duodenojejunostomy or the 21 gastrojejunostomy in the case of DGE can be performed. In both groups, the nasogastric tube can be 22 removed as soon as mechanical ventilation is stopped, but the decision remains up to the surgeon in 23 charge. All patients will be further treated as it is routinely carried out in the respective surgical is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 7, 2021. ; https://doi.org/10.1101/2021.08.05.21260575 doi: medRxiv preprint Study outcomes and data collection schedule 1

The primary outcome is the occurrence of DGE grade A, B, or C (mild, moderate, and severe forms) up 3 to 30 days post-surgery. The assessment of DGE is objective and uses the obvious criterion of the 4 presence of a gastric tube as defined by the ISGPS in 2007. 4 Table 1 displays the different forms of 5 DGE classified by their clinical impact. All study patients should be classified with result DGE yes vs 6 no (irrespective of the clinical grading). A patient will be positive, if DGE is diagnosed within 30 days 7 after index operation. In both treatment groups, the overall DGE incidence within 30 days after the index 8 operation will be assessed as primary outcome measure. We chose the time period of 30 days to reliably 9 observe all occurring postoperative events of DGE because after this time interval it is very unlikely that 10 reinsertion of the nasogastric tube is causally linked to DGE. Several trials have already used this 11 primary endpoint. 23 12 13

To compare peri-and postoperative outcomes between both groups, the following patient-and surgeon-15 oriented secondary outcomes will be assessed: 16

Operation time [minutes], 18

Conversion from ppPD to prPD [yes/no] 20 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint 

During the screening visit (≥1 days before surgery), eligibility criteria will be assessed. Those patients 13 who refuse written informed consent for the trial but give informed consent for the StuDoQ|Pancreas 14 registry will be documented in the registry only. After providing informed consent to participate in the 15 trial, the patient's demographic and clinical characteristics, medical history, comorbidities, preoperative 16 diagnostics and laboratory will be assessed and documented. After randomisation, surgical intervention 17 will occur on day 0 with assessment of the operation details, intra-and perioperative parameters as well 18 as adverse events. A standard follow-up care will be performed. Follow-ups are scheduled on day 7, day 19 14 or the day of discharge (whichever occurs first), and on day 30 after study-related index operation. 20

Postoperative follow-up can occur as clinic visits or by phone with documentation of the primary and 21 secondary endpoints including serious adverse events. Table 2 summarizes the patient data collection. 22 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 7, 2021. ; https://doi.org/10.1101/2021.08.05.21260575 doi: medRxiv preprint

Complication rates and SAEs will be closely monitored for the assessment of safety. SAEs occurring in 2 the period from the day of randomisation to the end of the postoperative follow-up will be documented. 3 4 Data management, data security and quality control 5

This trial is nested within the StuDoQ|Pancreas registry documenting key parameters related to 7 pancreatic surgeries since September 2013 and uses the same infrastructure. Data acquisition is 8 performed by a browser-based eCRF system which is based on PHP and R software. 10 All study data 9

will be stored electronically in the StuDoQ|Pancreas registry. 10

In summary, using the IT-infrastructure of the registry provides the following advantages: (1) 11

Participation of institutions and documentation is already implemented. (2) The eCRF is already 12 All installations were made in compliance with the GDPR and are continuously monitored by the data 19 protection officers. All study data will be entered by the investigators or designated staff into the 20 StuDoQ eCRF and stored in pseudonymized form. Data management and quality control will be 21 performed using automatic data validation requests/ data entry plausibility checks within the eCRF and 22 on-site monitoring to ensure accuracy and enquire implausible or missing data on a regular basis. 23

Supplementary periodic validation checks performed by the data management team will also encompass 24 data derived by the randomisation tool REDCap and will take place on a regular basis. After web-based 25 data entry into the StuDoQ eCRF, data are automatically checked for completeness and plausibility. 26

Completeness of major quality indicators is mandatory for the inclusion in the annual institutional 27 reports and DGAV certification purposes. Missing or implausible items generate warning messages and 28 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 7, 2021. ; https://doi.org/10.1101/2021.08.05.21260575 doi: medRxiv preprint queries. Besides, the experience of recruiting centers is documented in the annual quality reports of the 1 registry (Supplemental File 2) . 2 A formal protocol of the registry detailing aims and regulations concerning informed consent, data 3 safety and publication issues was established by the DGAV and can be accessed at 4 http://www.dgav.de/studoq/datenschutzkonzept-und-publikationsrichtlinien.html (in German). This set 5 of rules governing the registry therefore applies to this trial as well. These strategies for data protection 6 regulation are based on the guidelines set forth by the Society for Technology, Methods and 7

Infrastructure for Networked Medical Research (TMF). 30 The approved concept of "decentralised patient 8

lists" of the TMF is applied, which allows re-identification only by the treating participating hospital. 9

10

As most study centres already participate in the StuDoQ|Pancreas or another organ-specific StuDoQ 12 registry, a high level of routine for data entry and verification can be assumed. As the initiation of the 13 first centres happened closely after the outbreak of the COVID-19 pandemic, sites were initiated by 14 virtual meetings. As part of a risk-based monitoring strategy, all centres will be visited on-site or 15 virtually after enrolment of the first 10-15 patients. Key data will be verified for 100% of patients. Trial 16 sites will then be assessed as being either with or without noticeable findings with respect to the trial 17 protocol, data quality and GCP. Monitoring will be performed by the study centre at the site of the 18 coordinating investigator at LMU Munich. The monitor (affiliated to the sponsor of the trial) reviews the 19 eCRF for completeness and accuracy and instructs site personnel to make any required corrections. 20

During monitoring visits, the monitor will ensure that data documented in the eCRF are in line with 21 underlying source data. Sites without noticeable problems will receive no further on-site monitoring 22

visits. Centres assessed as having noticeable problems will be visited again within four months. If 23 problems persist, visits will be repeated three times per year, and key data will be verified for at least 24 50% of patients at the respective site. If no more findings occur, monitoring visits will no longer be 25 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 7, 2021. ; https://doi.org/10.1101/2021.08.05.21260575 doi: medRxiv preprint

An independent data monitoring committee (DMC) has been established comprising of one clinical 2 expert in this field and one biostatistician. The DMC will monitor the trial progress as well as the 3 protocol adherence. All preliminary reports and the interim analysis will be discussed and reviewed for 4 accuracy and conclusiveness. The DMC will make recommendations to the principal investigator to 5 continue or terminate the study on the basis of the results from the pre-planned interim analysis. The 6

board will meet at the beginning of the study and at 6-months intervals thereafter, or as needed. 7 8

No patients were involved in setting the research question or the outcome measures, nor were they 10 involved in developing plans for participant recruitment, or the design and implementation of the study. 11

However, the rationale and objectives of this trial are of major concern for the target patient population 12 and 21.5% (95% CI [15.6%; 27.1%]) for ppPD patients. 5 Based on this result and our aim to detect a 20 clinically relevant difference between prPD and ppPD, we chose the following planning scenario: An 21 absolute risk difference of 10% in DGE between both groups is regarded as a minimum clinically 22 important effect, with 25% DGE risk in the ppPD and 15% in the prPD group. We expect that for 15% 23 of the patients in each group the corresponding DGE outcome cannot be assessed (e.g. due to dropout, 24 lost to follow-up or mortality). In this case, the binary outcome will be set to failure within the analysis. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 7, 2021. ; https://doi.org/10.1101/2021.08.05.21260575 doi: medRxiv preprint Therefore, a failure rate of 0.30 (=0.15+0.15) for the prPD and of 0.40 (=0.25+0.15) for the reference 1 group ppPD was assumed for the initial sample size calculation. 2

Due to the possible imprecision of the reported rates, a two-stage group sequential design was set up, 3

with one interim analysis after assessment of 50% of the target sample size. The critical values and the 4 test characteristics of this group sequential test design were calculated for a Wang & Tsiatis design with 5 boundary shape parameter Delta=0.23 (values of Delta between 0 and 0.5 give critical values ranging 6 between Pocock and O'Brien & Fleming tests). 32, 33 For a pre-specified significance level of 5% (two-7 sided) and event rates π prPD =0.3 and π ppPD =0.4 (odds ratio (OR) of 1.556), the power is 90.0% if both 8 stages consist of two times 246 patients randomised per group, thus resulting in a total number of 984 9 patients to be assigned to the trial (Supplemental file 3) . Assuming that about 70% of eligible patients 10 consent to study participation, about 1406 patients in total have to be screened (Figure 2) . 11 12

As soon as the primary endpoint has been assessed for 492 randomised patients in total (50% 14 information fraction), the interim analysis will be conducted to inform potential adaptations, with futility 15 stop based on the pre-defined boundaries. If the study continues to the second stage, sample size 16 adaptation will be applied according to Müller & Schäfer, 34 while controlling the overall 2-sided 5% 17 significance level. 18

To compensate for the loss of power due to post-randomisation dropouts (non-resectable/ 19 metastasized patients not being part of the principal analysis) and crossover patients (who did not 20 receive the allocated surgical procedure (prPD instead of ppPD)), which may diminish the observed 21 treatment difference, it might become necessary to increase the sample size accordingly within the scope 22 of the interim analysis aiming to achieve 90% power when analysing the per protocol set as the smallest 23 population. 21 A certain proportion of crossover patients being unavoidable in the case of pre-operative 24 randomisation was not considered in the initial sample size calculation as no data were available, and the 25 extent of the conversion rate is difficult to be foreseen. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 7, 2021. ; https://doi.org/10.1101/2021.08.05.21260575 doi: medRxiv preprint

Stopping is statistically based on rules derived from the primary interim result, however, also based on 2 the feasibility of patient accrual. 3

The trial will be stopped if the first-stage p-value resulting from the planned interim analysis lies below 4 0.0143 for efficacy to ensure the statistical validity of the applied two-stage group sequential design. It 5 will also be stopped prematurely if the interim analysis permits continuation of the trial, but the re-6 calculated sample size to achieve sufficient statistical power is infeasible or inefficiently high. Thus, this 7 design avoids prolonged recruitment in order to reach statistical power if the goal is unachievable (the 8 interim analysis cannot account for misspecification of the design parameters that may emerge from the 9 interim results) or, if early significance can be claimed. 10 11

The primary efficacy analysis will be based on three analysis sets. Patients deemed unresectable during 13 surgery (e.g. total pancreatectomy performed) will not be considered in any of the analysis sets, as the 14 primary aim of this trial is to estimate the intervention effect after a PD. 15

The modified intention-to-treat (mITT) set (FAS, full analysis set) comprises all patients in the group to 16 which they were randomised (converted patients remain in the intended ppPD group; non-resectable 17 patients not considered). Analysing the mITT set can be interpreted as a treatment policy approach 18 according to the estimands framework. 35 The per-protocol (PP) set consists of all patients treated per 19 protocol; patients with major protocol violations and crossover patients will be excluded, and no missing 20 data will be imputed (non-resectable patients not considered). In addition, the As-Treated (AT) set will 21 be analysed considering patients according to their actual, rather than randomised (intended) treatment 22 (i.e., converted patients analysed in the prPD group; non-resectable patients not considered). Non-23 resectability is handled by excluding those patients from all the analyses as they are not part of the 24 targeted population. Other post-randomisation events, like resection of adjacent organs, will be ignored. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 7, 2021. ; https://doi.org/10.1101/2021.08.05.21260575 doi: medRxiv preprint

The null hypothesis for the primary binary endpoint assumes that the 30-day DGE rate is equal in the 2 ppPD and prPD group. To account for the factor site used for stratifying the randomisation, the principal 3 model will include random intercepts for study site. To compare DGE rates between both groups in the 4 final analysis, a logistic random intercept model will be applied with treatment as fixed effect, adjusting 5 for the surgeon caseload (≥20 vs <20 procedures per year). The effect of the intervention will be 6 presented as the OR of DGE for prPD vs ppPD, together with its 95% CI. In addition, crude proportions 7 (DGE incidence) by treatment arm will be reported with an unadjusted OR and 95% CI, and a χ² test p-8

value. If not revised in the SAP, missing values will be replaced by means of the ICA-r method 9

proposed by Higgins et al. (Imputed Case Analysis incorporating available reasons for missing data). 36 10

The pre-planned interim analysis will be done in accordance with the ITT principle in the same way as 11 the final analysis. 12 13

Concerning secondary endpoints on clinical effectiveness, exploratory analyses will be performed 15 reporting appropriate summary measures as well as descriptive two-sided p-values. Random intercept 16 models will be applied: logistic regression for binary perioperative outcomes (e.g. 30-day all-cause 17 mortality); linear regression for log-transformed operation time and other continuous secondary 18 outcomes. These models will also include caseload as adjusting factor and as additional fixed effect. 19

The safety analysis includes calculation and comparison of frequencies and incidences of all 20 complications and SAEs in the prPD vs. ppPD group. These safety data will be tabulated and 21 descriptively summarized for each time point. 22

Exploratory subgroup analyses (subgroups e.g., tumour patients, extension of resection, the patient's 25 BMI, age) will be performed to investigate the heterogeneity of the treatment effect across both surgical 26 groups within the target population. Registry-specific analyses aim to describe the trial population 27 within the relevant StuDoQ|Pancreas registry population to assess selection processes at different 28 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 7, 2021. ; https://doi.org/10.1101/2021.08.05.21260575 doi: medRxiv preprint levels. 37 Further, a subgroup analysis will be performed for DGE grade A, and grade B or C combined 1 (considered being clinically relevant DGE). In a supplementary analysis, the impact of treatment in 2 hospitals of different care levels (basic, regular, and maximum) regarding DGE incidence will be 3 assessed and compared between both surgical groups. 4

Statistical analyses will be performed using the software package R version 4.1.0 or higher. 38 A full SAP 5 will be written ahead of the final database lock and commencement of analysis. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 7, 2021. ; https://doi.org/10.1101/2021.08.05.21260575 doi: medRxiv preprint CONCLUSION 1 As the first surgical registry-based RCT in Germany, PyloResPres is the largest multicentre trial to date 2 to evaluate the impact of two competing pancreatic head resection strategies (pylorus-reserving vs. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 7, 2021. ; https://doi.org/10.1101/2021.08.05.21260575 doi: medRxiv preprint committee (EC) was obtained. The protocol is based on the underlying project application which 1 received previous independent peer review as part of the grant funding process. Together with the 2 patient information sheets and consent forms the protocol was first approved by the primary EC of the 3 Medical Faculty of the Ludwig-Maximilians-Universität, Munich, Germany on 14 August 2019 4 (approval number 19-221). Amendments to the protocol will be submitted to the EC for review. 5

Individual written informed consent including consent to registry-based data collection will be obtained 6 from all eligible patients in the trial. Consent forms for the trial include consent for publication of results 7 in peer-reviewed journals. Relevant data protection rules for all analysed data will be enforced. 8 9

Following trial completion, data will be available for future secondary-use by participating centres of the 11 registry. The main results will be reported according to relevant guidelines such as the CONSORT 12 extension for trials using routinely collected data and the IDEAL framework and recommendations for 13 the evaluation of surgical interventions in RCTs (Stage 3), 16,39,40 and will be published in international 14 peer-reviewed scientific journals in this field. Authors and collaborators will be involved in reviewing 15 drafts of the manuscripts arising from this trial. Additionally, these results will be considered in German 16 treatment guidelines. Relevant information about the trial results will be disseminated to patient groups 17 (e.g., the German 'Arbeitskreis der Pankreatektomierten e.V.') and the trial website 18 (http://www.dgav.de/studoq/pylorespres.html). 19 20 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 7, 2021. ; https://doi.org/10.1101/2021.08.05.21260575 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint 

All data of the StuDoQ|Pancreas registry are stored in pseudonymized form, and any re-identification 6 can only be done by the treating, participating hospital. Individual participant data cannot be shared 7 publicly because participants did not explicitly consent to the sharing of their data as per the European 8

Union's General Data Protection Regulation (GDPR) and the corresponding German privacy laws. De-9

identified participant data and a data dictionary defining each field in the dataset will be made available 10 to researchers upon formal request and receipt of a signed data sharing agreement in accordance with the 11 data sharing policies of the LMU Munich, Germany. Data will be available through the Research Ethics 12

Board of the LMU Munich for researchers who meet the criteria for access to confidential data and after 13 approval of a methodologically sound research proposal. Requests for data access can be directed to is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 7, 2021. ; https://doi.org/10.1101/2021.08.05.21260575 doi: medRxiv preprint role in the development of the study design, and will not have a role in data collection, analysis, 1 interpretation of the results, manuscript development, or the decision to submit the final report for 2 publication. The protocol is based on the project application, which received previous peer review as 3 part of the grant funding process. The Medical Faculty of the Ludwig-Maximilians-Universität, Munich, 4

Germany, is the sponsor of the trial. and sponsor delegated person, has oversight for the trial. HB is responsible for the registry 12

infrastructure. BR is the study project manager, responsible for the study's quality assessment, and he 13 and JW are in charge of the overall trial management. As information scientist, CK is operating the 14 registry and responsible for data management, data verification and data quality assurance of the official 15 study database being part of the StuDoQ|Pancreas registry. Notably, we would like to acknowledge the patients for their willingness to participate in this research. 26

We are grateful to Thorsten Hahn and Cristina Burkert, both study assistants at the KCS 27 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 7, 2021. ; https://doi.org/10.1101/2021.08.05.21260575 doi: medRxiv preprint (Koordinationszentrum Chirurgische Studien) at the site of the coordinating investigator, for their effort 1 and project management activities. We also thank Arthur Gil (IBE, LMU Munich) for implementing the 2 REDCap-based randomisation tool. Further, we would like to thank the following members of the is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 7, 2021. ; https://doi.org/10.1101/2021.08.05.21260575 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 7, 2021. Upper panel: Possible reconstruction methods after ppPD as Roux-en-Y reconstruction a), or as single-3

loop omega-shaped reconstruction with b), or without c) an additional side-to-side jejunojejunal 4

anastomosis. 5

Lower panel: Possible reconstruction methods after prPD as Roux-en-Y reconstruction d), or as single-6

loop omega-shaped reconstruction with an additional side-to-side jejunojejunal anastomosis e). 7

The red arrows indicate pylorus preservation, and pylorus resection, respectively. 8 ppPD = Pylorus preservation in pancreatoduodenectomy; prPD = Pylorus resection in 9

pancreatoduodenectomy. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 7, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 7, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 7, 2021. 

Uncinate process first--a novel approach 2 for pancreatic head resection

Improvement of surgical results for 4 pancreatic cancer

A systematic review 6 and meta-analysis of pylorus-preserving versus classical pancreaticoduodenectomy for surgical 7 treatment of periampullary and pancreatic carcinoma

Delayed gastric emptying (DGE) after pancreatic 9 surgery: a suggested definition by the International Study Group of Pancreatic Surgery (ISGPS)

Meta-analysis of delayed gastric emptying after pylorus-12 preserving versus pylorus-resecting pancreatoduodenectomy

Delayed Gastric Emptying After 14 Pancreaticoduodenectomy: an Analysis of Risk Factors and Cost

The effect of pylorus removal on delayed gastric emptying after 17 pancreaticoduodenectomy: a meta-analysis of 2,599 patients

Pylorus Resection Does Not Reduce Delayed Gastric 19

Emptying After Partial Pancreatoduodenectomy: A Blinded Randomized Controlled Trial (PROPP 20 Study, DRKS00004191)

Impact of gastric resection 22 and enteric anastomotic configuration on delayed gastric emptying after pancreaticoduodenectomy: a 23 network meta-analysis of randomized trials

The pancreatic surgery 25 registry (StuDoQ|Pancreas) of the German Society for General and Visceral Surgery (DGAV) -26 presentation and systematic quality evaluation

Quality Indicators in Pancreatic Surgery: Lessons Learned from the 28

Transatlantic registries of pancreatic surgery in the 30 United States of America

Variation in pancreatoduodenectomy as 33 delivered in two national audits

Registry-Based Randomized Controlled Trials: A New 35 Paradigm for Surgical Research

SPIRIT 2013 explanation and elaboration: guidance 37 for protocols of clinical trials

CONSORT extension for the reporting of 1 randomised controlled trials conducted using cohorts and routinely collected data (CONSORT-2 ROUTINE): checklist with explanation and elaboration

The Adaptive designs CONSORT Extension (ACE) 4 statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use 5 an adaptive design

CONSORT Statement for Randomized 7 Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for 8 Nonpharmacologic Trial Abstracts

Society of General and Visceral Surgery

Evidence-based recommendations for blinding in surgical 12 trials

Insights into surgical trials: methodological 14 challenges and solutions

Pylorus-preserving pancreaticoduodenectomy

Whipple) versus pancreaticoduodenectomy (classic Whipple) for surgical treatment of periampullary 17 and pancreatic carcinoma

Effect of antecolic or retrocolic reconstruction of the 19 gastro/duodenojejunostomy on delayed gastric emptying after pancreaticoduodenectomy: a meta-20 analysis

Classification of surgical complications: a new proposal 22 with evaluation in a cohort of 6336 patients and results of a survey

The Clavien-Dindo classification of surgical 24 complications: five-year experience

Group Sequential Methods with Applications to Clinical Trials

Approximately optimal one-parameter boundaries for group sequential 6 trials

A general statistical principle for changing a design any time during the 8 course of a trial

Step 4 (Final 11 Version adopted on

Imputation methods for missing outcome data in meta-14 analysis of clinical trials

Commentary: On the levels of patient selection in registry-based 16 randomized controlled trials

R: A language and environment for statistical computing

No surgical innovation without evaluation: the 20 IDEAL recommendations

Standardizing and monitoring the delivery of surgical 22 interventions in randomized clinical trials

All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf 19 (available on request from the corresponding author) and declare: 20All authors report grants from the German Research Foundation during the conduct of the study. 21The authors declare that no conflict of interest exist. 22